PALO ALTO, Calif., April 16, 2025 (GLOBE NEWSWIRE) Scilex Holding Company (Nasdaq: SCLX), a pioneering company specializing in the development of non-opioid pain management solutions, has announced a significant milestone in its therapeutic offerings. The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for Gloperba, the first and only liquid oral form of colchicine, which is indicated for the prophylaxis of painful gout flares in adults.

Colchicine is a well-established medication that has been used for decades to treat gout, a form of inflammatory arthritis characterized by sudden, severe attacks of pain, redness, and swelling in the joints. Gloperbas oral liquid formulation offers a crucial advantage by providing an alternative for patients who may have difficulty swallowing traditional pills. Each 5ml dose contains 0.6mg of colchicine, making it easier for individuals to manage their dosage according to their specific needs. This is particularly beneficial for patients with renal or hepatic impairment who may require more flexible dosing options.

In addition to its primary use for gout, colchicine has recently gained attention for its potential effectiveness in treating pericarditis, an inflammation of the pericardiumthe protective sac surrounding the heart. Symptoms of pericarditis can include sharp chest pain and discomfort, which may mimic a heart attack, making timely and effective treatment essential.

Under the provisions of the Orphan Drug Act, the FDA awards orphan designation to drugs intended to treat rare diseases affecting fewer than 200,000 individuals in the United States. This designation can provide various benefits, including market exclusivity for seven years post-approval, incentivizing the development of treatments for conditions that may not be commercially viable without such support.

Scilex Holding Company is committed to addressing high unmet medical needs within the pain management sector. The companys approach emphasizes acquiring, developing, and commercializing innovative therapies that are non-opioid based, aiming to improve patient outcomes while mitigating the risk of addiction associated with opioid medications.

In addition to Gloperba, Scilexs portfolio includes several other products designed to offer relief from pain without the risks associated with opioids. Notably, ZTlido is a topical lidocaine product approved for postherpetic neuralgia, and ELYXYB is recognized as a first-line treatment for acute migraine attacks.

With the recent advancements and FDA approvals, Scilex is positioned to make a significant impact in the field of pain management. For more information regarding Scilex Holding Company and its innovative product lineup, visit